NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated ...2 days ago · The latest price target for Applied Therapeutics ( NASDAQ: APLT) was reported by Baird on Tuesday, April 25, 2023. The analyst firm set a price target for 14.00 expecting APLT to rise to within 12 ... Applied Therapeutics Inc. APLT.N. Latest Trade. 2.66 USD. 0.35. +15.15% As of Jan 10, 2024. Values delayed up to 15 minutes. Today's Range. 2.25 - 2.66. 52 …Citigroup increased their target price on Applied Therapeutics from $5.00 to $7.00 and gave the stock a buy rating in a research report on Friday, February 16th.Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to analysts' expectations of $29.44 …Applied Therapeutics Inc stock performance at a glance. Check Applied Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. APLT Stock Performance. USD USD; Previous close: 3.75: 3.75: Day range: 3.73 - 5.833.73 - 5.83Year range: 0 - 50 - 5Applied Therapeutics Inc (NASDAQ: APLT) released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk ofOur mission is to create transformative treatments for patients with high unmet need conditions. Applied Therapeutics uses technological advances and abbreviated regulatory pathways, wherever possible, to design treatments for indications with significant unmet medical need. By taking a unique and focused approach, the company can significantly ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a br...Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 2/9/2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ...1 day ago · 7 Stocks to Buy and Hold Forever. Shares of APLT opened at $5.74 on Thursday. Applied Therapeutics has a 12 month low of $0.76 and a 12 month high of $6.00. The firm has a fifty day simple moving ... Jan 5, 2024 ... Use of technology ... Applied Therapeutics shares plunged almost 35% after the biotechnology firm reported disappointing results from its Phase 3 ...Feb 15, 2024 · Applied Therapeutics ( NASDAQ: APLT) rose ~14% premarket Thursday after the biotech said its Phase 3 INSPIRE trial for lead candidate govorestat (AT-007) reached main goals against a rare ... Company profile for Applied Therapeutics, Inc. (APLT) with a description, list of executives, contact details and other key facts. ... Stock Analysis Pro. Watchlist. Collapse. Applied Therapeutics, Inc. (APLT) NASDAQ: APLT · IEX Real-Time Price · USD. Add to Watchlist 2.730Get the latest stock price, quote, news and history of Applied Therapeutics, Inc. Common Stock (APLT), a biotechnology company that develops and commercializes …NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated ...2.3800 -0.07 (-2.86%) After hours: 08:00PM EST. Time Period: Jan 17, 2023 - Jan 17, 2024. Show: Historical Prices. Frequency: Daily. Apply. Currency in USD Download. Loading …Apr 24, 2023 · Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity. NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet ... If you need cash, aren’t happy with your investment returns or want to diversify your investments, you may have to liquidate some of your stocks. Buying and selling stocks is extre...Applied Therapeutics (APLT) sotck rises as its late-stage trial for lead asset govorestat hits main goals in Sorbitol Dehydrogenase ((SORD)) Deficiency. Read more here.CEO & Founder. Shoshana Shendelman, PhD founded Applied Therapeutics in 2016. She serves as President and Chief Executive Officer as well as Chair of the Board of Directors. Prior to founding Applied Therapeutics, she founded Clearpoint Strategy Group LLC, a boutique life sciences consulting firm, where she served as the Managing Director from ...February 23, 2024. EAM Investors LLC purchased a new position in Applied Therapeutics, Inc. ( NASDAQ:APLT - Free Report) in the 3rd quarter, according to its …Discover the latest data for Applied Therapeutics financials. From earnings and revenue to ROE, net margins, growth rates and more. ... Buying This Beaten-Down, Undervalued Rare Disease Company's Stock Jan 19. Price target increased to US$39.20 Jan 05. Applied Therapeutics Provides Regulatory Update on Galactosemia Program Jan 04.According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI...Our mission is to create transformative treatments for patients with high unmet need conditions. Applied Therapeutics uses technological advances and abbreviated regulatory pathways, wherever possible, to design treatments for indications with significant unmet medical need. By taking a unique and focused approach, the company can significantly ...The more transactions an expert has, the more significant the results become. 1. Denali Therapeutics. Markets Insider. Ticker: DNLI. Market cap: $2.49B. …AT-007 for Galactosemia. AT-007 is a once-daily oral compound that inhibits the enzyme Aldose Reductase. Aldose Reductase plays a crucial role in the pathogenesis of Galactosemia. Galactosemia is a rare, slowly progressing metabolic disease caused by a genetic inability to break down the sugar galactose. Aldose Reductase converts …Get the latest Omega Therapeutics Inc (OMGA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Jan 5, 2024 · Applied Therapeutics (NASDAQ:APLT) stock is falling on Friday following the release of Phase 3 clinical trial data from the clinical-stage biopharmaceutical company. Applied Therapeutics-stock. Applied Therapeutics Inc Registered Shs Stock , APLT. 2.99 -0.03 -1.02% 03:21:32 PM. NAS. Add to watchlist. News. Analyst …Applied Therapeutics stock is tumbling on Friday as investors react to lackluster results from a Phase 3 clinical trial of AT-001.More From InvestorPlace The #1 AI Investment Might Be This Company ...shoshana Shendelman APLT stock SEC Form 4 insiders trading. shoshana has made over 11 trades of the Applied Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,968 units of APLT stock worth $7,817 on 30 November 2023.. The largest trade he's ever made was exercising 125,000 units of …The current price Applied Therapeutics (APLT) is trading at is $4.97, which is out of the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular ChannelsJan 23, 2024 · Applied Therapeutics Inc (APLT) stock is trading at $2.84 as of 1:05 PM on Tuesday, Jan 23, a rise of $0.09, or 3.09% from the previous closing price of $2.75. The stock has traded between $2.76 and $3.02 so far today. Volume today is light. Applied Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. APLT updated stock price target summary. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Applied Therapeutics, Inc. (APLT). See many years of revenue, expenses and profits or losses.Applied Therapeutics Stock Forecast. All Analysts Top Analysts Stock Price Forecast. The 2 analysts with 12-month price forecasts for APLT stock have an average target of 10.5, with a low estimate of 7.00 and a high estimate of 14. The average target predicts an increase of 95.17% from the current stock price of 5.38.NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates ...Jan 5, 2024 ... Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday. Here are some other stocks moving in today's mid-day session. Gainers. Ainos, Inc ...In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in r...Applied Therapeutics Inc stock price live 3.13, this page displays NASDAQ APLT stock exchange data. View the APLT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Applied Therapeutics Inc real time stock price chart below.Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therape...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up t...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...Feb 15, 2024 · Applied Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 4 buy ratings, 2 hold ratings, and 0 sell ratings. What was the 52-week low for ... Company profile page for Applied Therapeutics Inc including stock price, company news, executives, ... Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company.Feb 16, 2024 ... Indeed, Applied Therapeutics (NASDAQ:APLT) stock is up 221% in the last year, providing strong gains for shareholders. Having said that ...Applied Therapeutics Stock Prediction 2030. In 2030, the Applied Therapeutics stock will reach $ 123.87 if it maintains its current 10-year average growth rate. If this Applied Therapeutics stock prediction for 2030 materializes, APLT stock willgrow 2,539.43% from its current price. Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past...leadership. Applied Therapeutics is led by an experienced team united by a commitment to develop urgently needed treatments for patients with high unmet medical need. The company’s Board of Directors has diverse and deep experience across business, medicine, law and finance. The company’s Scientific Advisory Board is composed of ... 5 days ago · According to the issued ratings of 1 analysts in the last year, the consensus rating for Applied Therapeutics stock is Buy based on the current 1 buy rating for APLT. The average twelve-month price prediction for Applied Therapeutics is $10.50 with a high price target of $14.00 and a low price target of $7.00. The average one-year price target for Applied Therapeutics (NasdaqGM:APLT) has been revised to 9.44 / share. This is an increase of 20.65% from the prior estimate of 7.82 dated January 16, 2024.In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this p...Based on 2 Wall Street analysts offering 12 month price targets for Applied Therapeutics in the last 3 months. The average price target is $10.50 with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 95.17% change from the last price of $5.38. Applied Therapeutics Inc Stock forecast & analyst price target predictions based on 2 analysts offering 12-months price targets for APLT in the last 3 months.Jan 4, 2024 · NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated ... Jan 3, 2024 · Grandbrothers. Applied Therapeutics (NASDAQ:APLT) stock jumped 10% in late morning trading Wednesday after the company said it has submitted applications for FDA and EU approval of its drug ... NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced successful completion of a recent pre-New Drug Application (“NDA”) …GreenApple78. Applied Therapeutics (NASDAQ:APLT) stock plunged 30% in post-market trading Thursday after the biotech company reported mixed results from a Phase 3 study of its drug AT-001 and said ...Apr 24, 2023 · Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity. NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet ... See Applied Therapeutics, Inc. (APLT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy. (GlobeNewswire) +6.91%. Oct-09-22 09:13AM. Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62. (Simply Wall St.) Applied Therapeutics Inc stock price live 5.66, this page displays NASDAQ APLT stock exchange data. View the APLT premarket stock price ahead of the market session or assess the after hours quote.Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to analysts' expectations of $29.44 …Applied Therapeutics Stock Prediction 2030. In 2030, the Applied Therapeutics stock will reach $ 123.87 if it maintains its current 10-year average growth rate. If this Applied Therapeutics stock prediction for 2030 materializes, APLT stock willgrow 2,539.43% from its current price. Stock Price & Overview. 1.62K followers. $5.13 -0.18 ( -3.39%) 4:00 PM 02/21/24. NASDAQ | $USD | Pre-Market: $5.40 +0.27 (+5.26%) 7:32 AM. Summary. Ratings. Financials. …Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday. Here are some other stocks moving in today's mid-day session. Gainers. Ainos, Inc.(NASDAQ: AIMD) jumped 112.6% to $3.6805 after falling more than 12% on Thursday. Revelstone Capital Acquisition Corp. (NASDAQ: RCAC) shares climbed 89.6% to $10.71.Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy. AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 treatment resulted in a statistically significant difference in cardiac functional capacity …NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has completed its public offering of 3,152,712 …Jan 5, 2024 · Applied Therapeutics stock is sliding lower on Friday alongside clinical trial results. A Phase 3 clinical trial of AT-001 failed to meet its primary endpoint. Even so, APLT is planning to ... Get the latest information on Applied Therapeutics Inc. (APLT), a biopharmaceutical company that develops and commercializes products for …Applied Therapeutics Inc (ZB_58319995.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Applied Therapeutics Inc | Nasdaq ... NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has completed its public offering of 3,152,712 …EAM Investors LLC purchased a new position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 391,595 shares of the company's stock, valued at approxApplied Therapeutics, Inc. est une société biopharmaceutique au stade clinique. La société se concentre sur le développement d'un portefeuille de produits ...APLT: Applied Therapeutics Inc Stock Price Quote - NASDAQ GM - Bloomberg. Bloomberg. Connecting decision makers to a dynamic network of information, people …In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in r...Applied Therapeutics Inc stock performance at a glance. Check Applied Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. APLT Stock Performance. USD USD; Previous close: 3.75: 3.75: Day range: 3.73 - 5.833.73 - 5.83Year range: 0 - 50 - 5Jul 6, 2020 ... The short attack, pulling no punches, says: “We believe that Applied Therapeutics' stock is wildly overvalued and that its prospects for ...Applied Therapeutics Inc. Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY. Applied Therapeutics, Inc. Common Stock (APLT) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Fintel reports that on February 22, 2024, Leerink Partners initiated coverage of Applied Therapeutics (NasdaqGM:APLT) with a Outperform recommendation. As of …Les Funtleyder is a healthcare portfolio manager at E Squared Capital Management and currently serves as the Chief Financial Officer for Applied Therapeutics. He was formerly the director of strategic investments for Opko Health and held roles as strategist and portfolio manager for Miller Tabak Health Transformation Fund, Provident Advisors, and …Applied Therapeutics Inc. Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY. EAM Investors LLC purchased a new position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 391,595 shares of the company's stock, valued at approxApplied Therapeutics. APLT. $5.60 ... as of February 22 4:00:00 PM EST. Applied Therapeutics (APLT) Stock Price Performance. Applied Therapeutics (APLT) Stock Key Data. Summary Additional Data ... Jan 5, 2024 · A 6% change in cardiac functional capacity has been shown to predict long-term survival and hospitalization for heart failure. The effect of AT-001 was dose-dependent, with the low dose (1000mg ... In 2030, the Applied Therapeutics stock will reach $ 73.38 if it maintains its current 10-year average growth rate. If this Applied Therapeutics stock prediction for 2030 materializes, APLT stock willgrow 2,539.43% from its current price. Complete Applied Therapeutics Inc. stock information by Barron's. View real-time APLT stock price and news, along with industry-best analysis.
Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD .... Flutter kicks
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated ...Business description. Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against ...Applied Therapeutics Stock Prediction 2030. In 2030, the Applied Therapeutics stock will reach $ 123.87 if it maintains its current 10-year average growth rate. If this Applied Therapeutics stock prediction for 2030 materializes, APLT stock willgrow 2,539.43% from its current price. The following information was filed by Applied Therapeutics Inc. (APLT) on Thursday, March 23, 2023 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the …Thanksgiving is a time of gratitude, family, and gathering around a bountiful meal. While it’s often seen as a holiday for children, adults can also find joy and relaxation during ...Short interest for Applied Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Applied Therapeutics's stock. Short interest data is updated every ... Jul 6, 2020 ... The short attack, pulling no punches, says: “We believe that Applied Therapeutics' stock is wildly overvalued and that its prospects for ...AT-007 is Applied Therapeutics’ lead investigational treatment, which could change the lives of people living with SORD Deficiency, as well as other diseases caused by Aldose Reductase. AT-007 has the potential to be the first FDA-approved therapy for SORD Deficiency. Applied Therapeutics initiated a pivotal trial in the 4th quarter of 2021.Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD ...Applied Therapeutics Inc (NASDAQ:APLT) shares jumped about 79% over the past five days through February 22. These gains came after Applied Therapeutics Inc (NASDAQ:APLT) said its Phase 3 INSPIRE ...NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has entered into a definitive securities purchase …Jan 5, 2024 · Applied Therapeutics stock is sliding lower on Friday alongside clinical trial results. A Phase 3 clinical trial of AT-001 failed to meet its primary endpoint. Even so, APLT is planning to ... .